• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脓毒症相关急性呼吸窘迫综合征的研究进展与发病机制

Advanced development and mechanism of sepsis-related acute respiratory distress syndrome.

作者信息

Gong Huankai, Chen Yao, Chen Meiling, Li Jiankang, Zhang Hong, Yan Shijiao, Lv Chuanzhu

机构信息

Emergency and Trauma College, Hainan Medical University, Haikou, China.

Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University, Haikou, China.

出版信息

Front Med (Lausanne). 2022 Nov 14;9:1043859. doi: 10.3389/fmed.2022.1043859. eCollection 2022.

DOI:10.3389/fmed.2022.1043859
PMID:36452899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9701739/
Abstract

The introduction of the Sepsis 3.0 guidelines in 2016 improved our understanding of sepsis diagnosis and therapy. Personalized treatment strategies and nursing methods for sepsis patients are recommended in the "Save Sepsis Campaign" in 2021. However, mortality in sepsis patients remains high. Patients with sepsis-related acute respiratory distress syndrome account for around 30% of them, with fatality rates ranging from 30 to 40%. Pathological specimens from individuals with sepsis-related ARDS frequently demonstrate widespread alveolar damage, and investigations have revealed that pulmonary epithelial and pulmonary endothelial injury is the underlying cause. As a result, the purpose of this work is to evaluate the mechanism and research progress of pulmonary epithelial and pulmonary endothelial damage in sepsis-related ARDS, which may provide new directions for future research, diagnosis, and therapy.

摘要

2016年《脓毒症3.0指南》的推出增进了我们对脓毒症诊断和治疗的理解。2021年的“拯救脓毒症运动”推荐了针对脓毒症患者的个性化治疗策略和护理方法。然而,脓毒症患者的死亡率仍然很高。脓毒症相关急性呼吸窘迫综合征患者约占其中的30%,死亡率在30%至40%之间。脓毒症相关急性呼吸窘迫综合征患者的病理标本经常显示广泛的肺泡损伤,研究表明肺上皮和肺内皮损伤是其根本原因。因此,这项工作的目的是评估脓毒症相关急性呼吸窘迫综合征中肺上皮和肺内皮损伤的机制及研究进展,这可能为未来的研究、诊断和治疗提供新的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/927a/9701739/3356cd9e74dc/fmed-09-1043859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/927a/9701739/3356cd9e74dc/fmed-09-1043859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/927a/9701739/3356cd9e74dc/fmed-09-1043859-g0001.jpg

相似文献

1
Advanced development and mechanism of sepsis-related acute respiratory distress syndrome.脓毒症相关急性呼吸窘迫综合征的研究进展与发病机制
Front Med (Lausanne). 2022 Nov 14;9:1043859. doi: 10.3389/fmed.2022.1043859. eCollection 2022.
2
Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome.肺上皮损伤和炎症的生物标志物可区分患有急性呼吸窘迫综合征的严重脓毒症患者。
Crit Care. 2013 Oct 24;17(5):R253. doi: 10.1186/cc13080.
3
Acute respiratory distress syndrome.急性呼吸窘迫综合征。
Nat Rev Dis Primers. 2019 Mar 14;5(1):18. doi: 10.1038/s41572-019-0069-0.
4
Cell therapy for the treatment of sepsis and acute respiratory distress syndrome.用于治疗败血症和急性呼吸窘迫综合征的细胞疗法。
Ann Transl Med. 2017 Nov;5(22):446. doi: 10.21037/atm.2017.08.28.
5
Endothelial dysfunction triggers acute respiratory distress syndrome in patients with sepsis: a narrative review.内皮功能障碍引发脓毒症患者的急性呼吸窘迫综合征:一项叙述性综述。
Front Med (Lausanne). 2023 Jun 2;10:1203827. doi: 10.3389/fmed.2023.1203827. eCollection 2023.
6
The epidemiology of acute respiratory distress syndrome in patients presenting to the emergency department with severe sepsis.急诊科以严重脓毒症就诊的急性呼吸窘迫综合征患者的流行病学。
Shock. 2013 Nov;40(5):375-81. doi: 10.1097/SHK.0b013e3182a64682.
7
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS.人类脓毒症中的内皮生物标志物:急性呼吸窘迫综合征的发病机制与预后
Pulm Circ. 2018 Apr-Jun;8(2):2045894018769876. doi: 10.1177/2045894018769876. Epub 2018 Mar 26.
8
Preventative Management of Sepsis-Induced Acute Respiratory Distress Syndrome in the Geriatric Population.老年人群中脓毒症诱发的急性呼吸窘迫综合征的预防性管理
Cureus. 2023 Feb 6;15(2):e34680. doi: 10.7759/cureus.34680. eCollection 2023 Feb.
9
Acute respiratory distress syndrome and acute lung injury.急性呼吸窘迫综合征和急性肺损伤。
Postgrad Med J. 2011 Sep;87(1031):612-22. doi: 10.1136/pgmj.2011.118398. Epub 2011 Jun 4.
10
Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993.急性呼吸窘迫综合征(ARDS)患者生存率的提高:1983 - 1993年。
JAMA. 1995 Jan 25;273(4):306-9.

引用本文的文献

1
Considering local immunity for innovative immunomodulatory approaches: pulmonary sepsis as a use case.考虑用于创新免疫调节方法的局部免疫:以肺部脓毒症为例
Front Immunol. 2025 Aug 7;16:1627313. doi: 10.3389/fimmu.2025.1627313. eCollection 2025.
2
Exploring the pathogenesis of acute lung injury and its treatment through Traditional Chinese Medicine: a state-of-the-art review.探索急性肺损伤的发病机制及其中医药治疗:一项最新综述。
Front Pharmacol. 2025 Jul 31;16:1592458. doi: 10.3389/fphar.2025.1592458. eCollection 2025.
3
Identification of Diagnostic Biomarkers and Therapeutic Targets in Sepsis-Associated ARDS via Combining Bioinformatics with Machine Learning Analysis.

本文引用的文献

1
METTL3-Mediated N6-Methyladenosine Modification of Trim59 mRNA Protects Against Sepsis-Induced Acute Respiratory Distress Syndrome.METTL3 介导的 Trim59 mRNA N6-甲基腺苷化修饰可防止脓毒症诱导的急性呼吸窘迫综合征。
Front Immunol. 2022 May 25;13:897487. doi: 10.3389/fimmu.2022.897487. eCollection 2022.
2
Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches.急性肺损伤中的内皮细胞转胞吞作用:新出现的机制与治疗方法
Front Physiol. 2022 Mar 31;13:828093. doi: 10.3389/fphys.2022.828093. eCollection 2022.
3
Novel biomarkers for acute respiratory distress syndrome: genetics, epigenetics and transcriptomics.
通过生物信息学与机器学习分析相结合鉴定脓毒症相关急性呼吸窘迫综合征的诊断生物标志物和治疗靶点
J Inflamm Res. 2025 Jul 18;18:9523-9536. doi: 10.2147/JIR.S529689. eCollection 2025.
4
Quercetin Confers Protection against Sepsis-Related Acute Respiratory Distress Syndrome by Suppressing ROS/p38 MAPK Pathway.槲皮素通过抑制ROS/p38丝裂原活化蛋白激酶信号通路对脓毒症相关急性呼吸窘迫综合征起保护作用。
Chin J Integr Med. 2025 Jun 24. doi: 10.1007/s11655-025-3927-5.
5
LncRNA HOXA-AS2 Can Predict the Risk of Acute Respiratory Distress Syndrome and 28-Day Mortality in Patients With Sepsis.长链非编码RNA HOXA-AS2可预测脓毒症患者急性呼吸窘迫综合征的风险及28天死亡率。
Clin Respir J. 2025 May;19(5):e70082. doi: 10.1111/crj.70082.
6
Inhibition of RACK1-Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome.抑制RACK1介导的NLRP3寡聚化(活性构象)可改善急性呼吸窘迫综合征。
Adv Sci (Weinh). 2025 Jul;12(27):e2411355. doi: 10.1002/advs.202411355. Epub 2025 May 11.
7
Bosutinib mitigates inflammation in experimental sepsis.博舒替尼可减轻实验性脓毒症中的炎症反应。
Eur J Clin Invest. 2025 Sep;55(9):e70055. doi: 10.1111/eci.70055. Epub 2025 Apr 28.
8
Development and validation of a Nomogram for the prediction of patients with sepsis-induced multiple organ dysfunction syndrome.用于预测脓毒症诱导的多器官功能障碍综合征患者的列线图的开发与验证
Pak J Med Sci. 2025 Apr;41(4):1036-1046. doi: 10.12669/pjms.41.4.10421.
9
Dynamic Immune Indicator Changes as Predictors of ARDS in ICU Patients with Sepsis: A Retrospective Study.动态免疫指标变化作为脓毒症重症监护病房患者急性呼吸窘迫综合征的预测指标:一项回顾性研究
Int J Gen Med. 2025 Mar 1;18:1163-1172. doi: 10.2147/IJGM.S501252. eCollection 2025.
10
Lung immune incompetency after mild peritoneal sepsis and its partial restoration by type 1 interferon: a mouse model study.轻度腹膜脓毒症后的肺免疫功能不全及其通过1型干扰素的部分恢复:一项小鼠模型研究
Intensive Care Med Exp. 2024 Dec 20;12(1):119. doi: 10.1186/s40635-024-00707-7.
急性呼吸窘迫综合征的新型生物标志物:遗传学、表观遗传学和转录组学。
Biomark Med. 2022 Feb;16(3):217-231. doi: 10.2217/bmm-2021-0749. Epub 2022 Jan 14.
4
Clinical and biological markers for predicting ARDS and outcome in septic patients.用于预测脓毒症患者 ARDS 及结局的临床和生物学标志物。
Sci Rep. 2021 Nov 22;11(1):22702. doi: 10.1038/s41598-021-02100-w.
5
TLR4-IN-C34 Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses via Downregulating TLR4/MyD88/NF-κB/NLRP3 Signaling Pathway and Reducing ROS Generation in BV2 Cells.TLR4-IN-C34 通过下调 TLR4/MyD88/NF-κB/NLRP3 信号通路和减少 BV2 细胞中 ROS 的产生来抑制脂多糖刺激的炎症反应。
Inflammation. 2022 Apr;45(2):838-850. doi: 10.1007/s10753-021-01588-8. Epub 2021 Nov 2.
6
Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review.调节脓毒症、急性呼吸窘迫综合征和胰腺炎患者炎症及免疫反应的治疗方法:专家意见综述
Cureus. 2021 Sep 30;13(9):e18393. doi: 10.7759/cureus.18393. eCollection 2021 Sep.
7
The Role of Epithelial Damage in the Pulmonary Immune Response.上皮损伤在肺部免疫反应中的作用。
Cells. 2021 Oct 15;10(10):2763. doi: 10.3390/cells10102763.
8
Assessment of Alveolar Macrophage Dysfunction Using an Model of Acute Respiratory Distress Syndrome.使用急性呼吸窘迫综合征模型评估肺泡巨噬细胞功能障碍
Front Med (Lausanne). 2021 Sep 29;8:737859. doi: 10.3389/fmed.2021.737859. eCollection 2021.
9
Advancing precision medicine for acute respiratory distress syndrome.推进急性呼吸窘迫综合征精准医学。
Lancet Respir Med. 2022 Jan;10(1):107-120. doi: 10.1016/S2213-2600(21)00157-0. Epub 2021 Jul 23.
10
Acute respiratory distress syndrome is associated with impaired alveolar macrophage efferocytosis.急性呼吸窘迫综合征与肺泡巨噬细胞的胞噬作用受损有关。
Eur Respir J. 2021 Sep 9;58(3). doi: 10.1183/13993003.00829-2021. Print 2021 Sep.